Bruce D. Jackson
Stock Analyst at Benchmark
(2.41)
# 2,500
Out of 5,140 analysts
9
Total ratings
50%
Success rate
16.63%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAS Exact Sciences | Downgrades: Hold | n/a | $102.47 | - | 2 | Nov 24, 2025 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.27 | +270.37% | 1 | Nov 20, 2025 | |
| HUMA Humacyte | Maintains: Buy | $14 → $11 | $1.04 | +962.80% | 1 | Nov 13, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $162.50 | -18.77% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $14 → $7 | $0.34 | +1,945.59% | 1 | Sep 15, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $3 → $21 | $6.56 | +220.12% | 1 | Sep 15, 2025 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $3 → $2 | $0.58 | +244.53% | 1 | Sep 10, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $4.82 | +543.15% | 1 | Sep 10, 2025 |
Exact Sciences
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $102.47
Upside: -
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.27
Upside: +270.37%
Humacyte
Nov 13, 2025
Maintains: Buy
Price Target: $14 → $11
Current: $1.04
Upside: +962.80%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $162.50
Upside: -18.77%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $14 → $7
Current: $0.34
Upside: +1,945.59%
Unicycive Therapeutics
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $3 → $21
Current: $6.56
Upside: +220.12%
Harvard Bioscience
Sep 10, 2025
Maintains: Speculative Buy
Price Target: $3 → $2
Current: $0.58
Upside: +244.53%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $4.82
Upside: +543.15%